Oncbiomune Pharmaceuticals Inc., of Baton Rouge, La., enlisted Princeton, N.J.-based Theradex Oncology to run a phase II study of its Proscavax vaccine for the treatment of prostate-specific antigen-recurrent prostate cancer in hormone-naive patients.